Publications
84
Citations
1,035
Est. group size
~1
Recurring co-author estimate
Active years
20
Publishing since 2006
Typically publishes in teams of ~11 · 3% small-team papers (≤3 authors) · across 22 venues
- Abstract 3628: Associations between per and polyfluoroalkyl substances (PFAS) and inflammatory markers in a racially diverse cohort of breast cancer patients
Cancer Research · 2025
- Abstract 5753: Multi-omic analysis links neighborhood disadvantage to elevated stress hormones and tumorigenic markers in ER+ breast cancer patient plasma and tumor samples
Cancer Research · 2025
- Abstract P2-09-27: Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)
Clinical Cancer Research · 2025
- Multiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples
Journal of Proteome Research · 2025
- Risk of VTE in TNBC treated with neoadjuvant immunotherapy.
Journal of Clinical Oncology · 2024
- Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score
Journal of the National Comprehensive Cancer Network · 2024
- Abstract 7485: Microfluidic detection of dual positive cells in whole blood of metastatic breast cancer patients
Cancer Research · 2024
- Abstract PO5-20-04: A Phase II Study of Ribociclib and Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer Research · 2024
- Rationale and Design for Time Restricted Eating (Tre) and Mediterranean Diet Tre (Medtre) During Chemotherapy for Breast Cancer
SSRN Electronic Journal · 2024
- Abemaciclib dose escalation to maintain intensity (ADE-MI).
Journal of Clinical Oncology · 2024
- Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs.
Journal of Clinical Oncology · 2024
- Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer
JAMA Oncology · 2023
- Identification of metabolic pathways contributing to ER+ breast cancer disparities using a machine-learning pipeline
Scientific Reports · 2023
- Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
Neuro-Oncology Advances · 2023
- Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
Cancer Research · 2023
- Journal of Clinical Oncology×21
- Cancer Research×18
- JAMA Oncology×3
- Proceedings of the National Academy of Sciences×3
- American Journal of Clinical Oncology×2
- Anne F. Schott
Medicine · University of Michigan
- Preeti Sudheendra
Medicine · The Ohio State University
- Gilbert Bader
Medicine · The Ohio State University
- Mehta Rs
Medicine · University of Michigan
- Sagar Sardesai
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile